Rezolute, Inc.
NASDAQ: RZLT0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Nevan Charles Elam
- Employees
- 74
- Headquarters
- Redwood City, United States
- IPO year
- 2013
- Market cap
- $484.4M
- Website
- https://www.rezolutebio.com
Loading RZLT…
Loading profile data…Frequently asked questions about RZLT
What does Rezolute, Inc. (RZLT) do?
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultr...
Where does RZLT trade?
Rezolute, Inc. (RZLT) trades on the NASDAQ.
What sector is RZLT in?
Rezolute, Inc. (RZLT) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Rezolute, Inc.?
Nevan Charles Elam is the chief executive officer of Rezolute, Inc. (RZLT).
Where is Rezolute, Inc. headquartered?
Rezolute, Inc. is headquartered in United States.
Does RZLT pay a dividend?
Rezolute, Inc. (RZLT) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did RZLT go public?
Rezolute, Inc. (RZLT) completed its initial public offering in 2013.